Kazia Therapeutics Limited (KZIA)
NASDAQ: KZIA · Real-Time Price · USD
6.15
-0.41 (-6.25%)
Jan 29, 2026, 3:24 PM EST - Market open
Kazia Therapeutics Employees
Kazia Therapeutics had 6 employees as of June 30, 2025. The number of employees decreased by 1 or -11.76% compared to the previous year.
Employees
6
Change (1Y)
-1
Growth (1Y)
-11.76%
Revenue / Employee
$199,851
Profits / Employee
-$2,262,069
Market Cap
67.01M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 6 | -1 | -11.76% |
| Jun 30, 2024 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pliant Therapeutics | 171 |
| Immunic | 90 |
| PolyPid | 60 |
| Mereo BioPharma Group | 36 |
| Equillium | 35 |
| Gain Therapeutics | 25 |
| Annovis Bio | 15 |
| Pelthos Therapeutics | 11 |
KZIA News
- 2 days ago - Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer - PRNewsWire
- 21 days ago - Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End - PRNewsWire
- 5 weeks ago - Kazia Therapeutics Regains Full Nasdaq Listing Compliance - PRNewsWire
- 7 weeks ago - Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+ - PRNewsWire
- 2 months ago - What's Going On With Cancer Firm Kazia Therapeutics - Benzinga
- 2 months ago - Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities - PRNewsWire
- 2 months ago - Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy - PRNewsWire
- 3 months ago - Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner - PRNewsWire